Clinical Trials Logo

JAK2 Mutation clinical trials

View clinical trials related to JAK2 Mutation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04527666 Not yet recruiting - Clinical trials for Myeloproliferative Neoplasm

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Start date: October 1, 2020
Phase:
Study type: Observational

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.